Showing 2791-2800 of 5771 results for "".
- EYE-GO Secures Strategic Investment from Topcon Healthcarehttps://modernod.com/news/eye-go-secures-strategic-investment-from-topcon-healthcare/2482807/EYE-GO, a Danish MedTech company, today announced that Topcon Healthcare, Inc will become a strategic investor in their company. According to EYE-GO, the collaboration reflects a shared vision to revolutionize chronic eye disease management through evidence-
- ScienceBased Health Expands Its Ophthalmology Clinical Advisory Panelhttps://modernod.com/news/sciencebased-health-expands-its-ophthalmology-clinical-advisory-panel/2482806/ScienceBased Health (SBH) today announced the addition of Nicole Fram, MD, Jennifer Loh, MD and Gary Wörtz, MD to its Ophthalmology Clinical Advisory Panel. The organi
- Intalight Receives CE Mark for its DREAM OCT Platformhttps://modernod.com/news/intalight-receives-ce-mark-for-its-dream-oct-platform-approal-for-commercialization-in-europe/2482804/Intalight announced it has received CE mark for its
- New World Medical Introduces Next-Generation Streamline Surgical Systemhttps://modernod.com/news/new-world-medical-introduces-next-generation-streamline-surgical-system-1/2482803/New World Medical has announced the launch of its enhanced Streamline Surgical System, which features a transparent tip designed to provide surgeons with improved visualization of key anatomical structures throughout the procedure. This latest advancement builds upon the original Streamline
- Bausch + Lomb Launches Zenlens CHROMA HOA in the UShttps://modernod.com/news/bausch-lomb-launches-zenlens-chroma-hoa-in-the-us/2482802/Bausch + Lomb announced the US launch of Zenlens CHROMA HOA scleral contact lenses. Designed to correct advanced higher-order aberrations (HOA), this custom, wavefront-guided scleral lens technology delivers enhanced vision and improves clarity by reducing symptoms such as halos an
- The Alliance for Healthcare from the Eye Launches to Transform Disease Detectionhttps://modernod.com/news/the-alliance-for-healthcare-from-the-eye-launches-to-transform-disease-detection/2482801/A coalition of healthcare leaders announced the launch of the 'Alliance for Healthcare from the Eye (AHE)' at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City. AHE is a cross-sector initiative
- Hoya Vision Care Presents New Data on Myopia Management Spectacle Lenses at ARVOhttps://modernod.com/news/hoya-vision-care-presents-new-data-on-myopia-management-spectacle-lenses-at-arvo/2482800/Hoya Vision Care announced new clinical evidence from three key clinical studies highlighting the impact of 'Defocus Incorporated Multiple Segments (DIMS)' technology. The results were presented as part of the company’s 2025 scientific program, 'Exploring New Frontiers in Myopia
- Genentech: Largest Real-World Studies Show Vabysmo’s Long-Term Benefits for Wet AMD, DMEhttps://modernod.com/news/genentech-largest-real-world-studies-show-vabysmos-long-term-benefits-for-wet-amd-dme/2482798/Genentech presented more than 20 abstracts across its ophthalmology portfolio at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Key studies highlight Vabysmo’s long-term ability to sustain vision improvements in patients with wet
- Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Resultshttps://modernod.com/news/isarna-therapeutics-presents-positive-phase-2-better-trial-final-results-at-arvo-2025/2482797/Isarna Therapeutics presented final positive results from its phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on May 6. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, shared data
- LumiThera’s LIGHTSITE Phase 3B Extension Trial Shows Extended Vision Improvement in Dry AMDhttps://modernod.com/news/lumitheras-phase-3b-extension-trial-topline-results-show-extended-vision-improvement-in-dry-amd-subjects/2482796/LumiThera announced the topline results from the LIGHTSITE 3B extension trial, a prospective, open-label trial in dry age-related macular degeneration (AMD) subjects. The extension trial followed subjects that completed the pivotal LIGHTSITE 3 trial